Testosterone Appears Safe for Hypogonadal Patients With Prostate Cancer

Share this content:
For hypogonadal men with prostate cancer, testosterone treatment seems oncologically safe.
For hypogonadal men with prostate cancer, testosterone treatment seems oncologically safe.

(HealthDay News) -- For hypogonadal men with prostate cancer, testosterone treatment seems oncologically safe, according to a study published in The Journal of Urology.

Jesse Ory, from the University of British Columbia in Vancouver, Canada, and colleagues identified a cohort of 82 hypogonadal men with prostate cancer treated with testosterone therapy. Patients (median age, 75.5 years) were followed for a median of 41 months.

The researchers found that in the entire cohort there was an increase in testosterone (P < 0.001) and prostate-specific antigen (P = 0.001).

The eight patients on active surveillance had an increase in prostate-specific antigen; none of the patients were upgraded to higher Gleason score and none had started definitive treatment. Among patients treated with radical prostatectomy, there was no biochemical recurrence; however, 6 percent of those treated with radiation therapy experienced biochemical recurrence.

It was not clear whether these cases were related to testosterone therapy. In the radical prostatectomy, radiation therapy, and active surveillance groups the mean prostate-specific antigen velocity was 0.001, 0.12, and 1.1 µg/L per year, respectively.

RELATED: Vasectomy Unlikely to Be a Causal Factor of Aggressive Prostate Cancer

"In the absence of randomized, placebo controlled trials, our study supports the hypothesis that testosterone therapy may be oncologically safe in hypogonadal men after definitive treatment or in those on active surveillance for prostate cancer," the authors write.

One author disclosed financial ties to Genyous.

Reference

  1. Ory J, Flannigan R, Lundeen C, et al. Testosterone Therapy in Patients with Treated and Untreated Prostate Cancer: Impact on Oncologic Outcomes. J Urol. 2016 Apri 28. doi: http://dx.doi.org/10.1016/j.juro.2016.04.069.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs